Solid compositions
The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
1. A solid oral dosage form comprising a solid solution which includes:
copovidone, and
optionally a pharmaceutically acceptable surfactant.
2. The solid dosage form of claim 1 , which is a tablet.
3. The solid dosage form of claim 2 , wherein said tablet is film coated.
4. The solid dosage form of claim 1 , which further comprises another anti-HCV agent.
5. A method of treating HCV infection, comprising administering the solid oral dosage form of claim 1 to a patient in need thereof.